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TCT-455
Evaluation of second generation DES in an ex-vivo model of stent thrombosis
Alexander Sheehy1, Leigh B Kleinert2, Stephen Pacetti1, Syed Hossainy1, Mikael
Trollsas1, Stuart K Williams2
1R&D, Abbott Vascular, Santa Clara, CA; 2University of Louisville, Louisville, KY
Background: Thrombosis remains a risk following all types of endovascular
intervention. Though considerable advances have been made in stent design, the design
factors leading to stent thrombosis—stent design, drug elution, and coatings—continue
to be improved and evaluated. It is critical that stents exhibit minimal surface
thrombogenicity to reduce the incidence of device-induced vessel thrombosis.
Methods: The left and right femoral artery of five domestic Yorkshire swine were
cannulated to create to an ex vivo blood shunt through polyethylene tubing with
silicone tubing sections to allow stent deployment before re-entry to the femoral vein.
3.0x18mm stents in the following groups were evaluated: bare metal stent (BMS, ML
VISION®), collagen coated BMS (BMS-c), XIENCE V® (XV), and Endeavor
Resolute (Res), and unstented silicone tubing (negative control). Six stents from each
group were inserted into the ex-vivo shunt system randomized in sequence. No
anticoagulation or antiplatelet agents were administered to the animals. Blood was
allowed to circulate through the shunt for 30 minutes, following which stents were
weighted for gravimetric assessment of thrombus burden and images were obtained.
Results: As expected, positive control collagen coated BMS exhibited the greatest
amount of thrombus, followed by BMS, then Endeavor Resolute. Xience V and
unstented silicone tubing had the least thrombus. The pre-stenting to post-stenting
weight differential of each was—BMS: 0.06±0.04, BMS-c: 0.10±0.02, Res:
0.021±0.003 (p<0.05 vs BMS, BMS-c), XV: 0.012±0.007 (p<0.05 vs BMS, BMS-c,
Res), Silicone tube: 0.010±0.011 (p<0.05 vs BMS, BMS-c, Res).
Conclusion: In a model of acute thrombogenicity, Xience V demonstrated the least
amount of thrombus in comparison to other second generation DES and BMS. This
preclinical thrombogenicity data appears to corroborate the low acute thrombosis rates
observed with Xience V in clinical practice.
TCT-456
Microarray Analysis for Nobori Biolimus A9 Eluting Stent and Xience V
Everolimus Eluting Stent in Porcine Coronary Artery
Arihiro Sumida, Selvamuthu Natarajan, Deepal Panchal, Jinsheng Li, Dongming
Hou, Nicholas Chronos, Jaipal Singh, Surendra Chavan
St Joseph’s Translational Research Institute, Atlanta, GA
Background: Drug eluting stents (DES) have decreased the rate of in-stent restenosis
and been used as one of the most important devices for treatment of coronary artery
disease. Although most drugs inhibit mammalian target of rapamycin (mTOR), the
biological effects of DES toward stented vessels remain unknown. We examined
transcript expression by microarray analysis in stented blood vessels implanted with
two types of new generation DES, Nobori and Xience V.
Methods: One month after stent implantation in porcine coronary arteries, all animals
were euthanized and stented arteries were harvested for a microarray analysis. In this
study, total RNA from stented vessel segments (Nobori: n=4, Xience V: n=3) or non-
stented vessel segments (Control: n=2) were evaluated by using Agilent gene arrays.
Significant genes were selected with a cutoff of p<0.05 and fold change >2.
Results: 3,239 of 40,424 genes were considered differentially expressed and 533 genes
for Nobori and 1,503 genes for Xience V were exclusively altered in each group. In
pathway specific gene expression analysis, the expression levels of interleikin -1β
(2.13-fold, p<0.05), IL-2 receptor γ (2.70-fold, p<0.05), matrix metalloproteinase 9
(2.38-fold, p<0.05), monocyte chemoattractant protein-1 (2.17-fold, p<0.05), regulated
upon activation, normal T cell expressed and secreted (3.85-fold, p<0.05), chemokine
receptor 7 (5.56-fold, p<0.05), tissue necrotic factor (2.70-fold, p<0.05), selectin P
ligand (2.44-fold, p<0.05) and integrin β2 (2.38-fold, p<0.05) were decreased in Nobori
compared to Xience V. Interestingly, Adiponectin, C1q and collagen domain containing
(ADIPOQ) gene showed different expression in both group (2.77-fold increase
compared to Xience V, p=0.012) as well as fractalkine (C-X3-C motif ligand 1) gene
expressed (2.38-fold decrease compared to Xience V, p=0.048).
Conclusion: Based on this preliminary microarray gene expression study, expression
of inflammatory cytokines and adhesion molecules involved in inflammatory and
immune reactions were downregulated in Nobori stented blood vessesls compared to
Xience V.
TCT-457
Evaluation of Drug Tissue Concentration Following Stenting in a Healthy
Rabbit Iliac Model
Alexander Sheehy1, Saami K Yazdani2, Ed Berger1, Rosy S Donn1, Tu D Ngo1,
Stephen Pacetti1, Syed Hossainy1, Frank D Kolodgie2, Renu Virmani2
1R&D, Abbott Vascular, Santa Clara, CA; 2CVPath, Inc, Gaithersburg, MD
Background: Drug eluting stents (DES) have significantly improved restenosis rates.
However, some DES have been shown to inhibit wound healing and re-
endothelialization, leading to an increased risk of late stent thrombosis (LST).
Prolonged drug tissue concentration has been implicated as a potential source of
delayed healing. Although in vitro models can assess the dose and time-dependent
release kinetics of DES, in vivo models are needed to provide a more clinically relevant
environment for drug tissue content. The purpose of this study was to assess the tissue
drug concentrations of stented iliac rabbit arteries for four different DES on a head-to-
head basis.
Methods: Four DES were evaluated: Cypher (SES, sirolimus), Endeavor Sprint (ZES-
S, Zotarolimus), Endeavor Resolute (ZES-R, Zotarolimus), and XIENCE V® (EES,
Everolimus). Stents were implanted into both healthy rabbit iliac arteries for durations
of 3, 14, 28, 42, and 90 days. Arterial drug concentrations were measured with liquid
chromatography-mass spectrometry (LCMS).
Results: A model was created for tissue concentration based upon duration, treatment
group, and interaction effects (p<0.01, r2=0.51). Both treatment and duration were
significant effectors of tissue concentration (p<0.001). The drug tissue concentration
curve for ZES-S was significantly higher at 3 days. At 90 days, tissue drug
concentration for ZES-R was significantly higher than the other three devices (ng/mg):
EES: 0.38±0.37, ZES-S: 1.25±0.83, SES: 1.27±0.52, ZES-R: 3.53±1.27, p<0.001 ZES-
R vs EES, ZES-S, and SES. Surprisingly, at 90 days the drug tissue concentration for
ZES-S was numerically higher than for EES, but not significantly so.
Conclusion: In a healthy rabbit iliac artery, tissue drug concentration following stenting
was different between the different drug eluting stents as a function of time. Tissue
drug concentration was greatest at early time points with ZES-S and at late time points
with ZES-R. Differences in tissue drug concentration and duration of drug in tissue
may have implications for DES efficacy and inhibition of healing.
TCT-458
Which Genes of the Nitric Oxide Pathway Contribute to Vascular Dysfunction
Following DES Implantation in Swine Coronary Arteries?
Selvamuthu K Natarajan, Traci Goodchild, Surendra Chavan, Michael Sweet,
Dongming Hou, Nicolas Chronos, Jai Pal Singh
Saint Joseph’s Translational Research Institute, Atlanta, GA
Background: Histological studies have shown that pig coronary arteries become
endothelialized within 30 days after the implantation of drug eluting stent (DES).
However, quantitative angiographic assessment shows vasoconstriction in response to
acetylcholine challenge, indicating abnormal endothelial function. The present study
was aimed to understand the molecular mechanism of endothelial dysfunction in DES
implanted vessels.
Methods: Either bare metal or drug eluting stents with different polymers or drug were
implanted in farm pigs in a total of 16 vessels. After 30 days, in vivo vascular function
was assessed by acetylcholine challenge test. Vessels were harvested for histology,
quantitative RT-PCR and western blot analysis. Specific analysis of nitric oxide
pathway genes was performed.
Results: In vivo quantitative angiography confirmed vasoconstriction and vasodilation
indicating the presence of endothelial dysfunction in DES implanted arteries. Real-
Time PCR showed a major upregulation of two of the NOS pathway genes, Arginase
(100-3000 fold) and DDAH (5-7 fold). Only a small but significant (2 fold) change in
eNOS gene expression was also observed. The gene expression changes were localized
in the intima and media as the majority of the tissue used was derived from the intima
and media. Histological evaluation showed higher angiogenesis in DES implanted
vessels as compared to the BMS implanted arteries. Our results suggest that increase
in eNOS gene expression may be related to the angiogenic response whereas high
arginase expression may deplete the substrate for NO generation and thereby contribute
to endothelial dysfunction. An increased expression of DDAH is expected to be
beneficial by reducing ADMA and superoxide generation.
Conclusion: Gene expression studies have provided new insight into the role of nitric
oxide pathway genes in vascular response and endothelial dysfunction observed in
DES implanted pig arteries. Our studies for the first time show that arginase and DDAH
may be important players in modulating vascular response in DES implanted coronary
arteries.
TCT-459
Pharmacokinetic Evaluation of Drug Eluting Stents in a Healthy and
Atherosclerotic Rabbit Iliac Model
Alexander Sheehy1, Saami K Yazdani2, Ed Berger1, Rosy S Donn1, Tu D Ngo1,
Stephen Pacetti1, Syed Hossainy1, Frank D Kolodgie2, Renu Virmani2
1R&D, Abbott Vascular, Santa Clara, CA; 2CVPath, Inc, Gaithersburg, MD
Background: Though drug eluting stents (DES) have significantly improved restenosis
rates, some (DES) have been shown to inhibit re-endothelialization, leading to an
increased risk of late stent thrombosis. An optimal DES design would deliver sufficient
drug to inhibit restenosis but have minimal impact on healing. Most pharmacokinetic
(PK) studies have been performed in healthy animals and the relevance of this patients
with atherosclerotic disease remains an open question. The purpose of this study was
to assess the tissue drug concentrations achieved with several DES in both healthy and
atherosclerotic rabbit iliac arteries.
Methods: Four DES were evaluated: Cypher (SES, Sirolimus), Endeavor Sprint (ZES,
Zotarolimus), Taxus Liberte (PES, Paclitaxel), and XIENCE V® (EES, Everolimus).
Stents were implanted into healthy and atherosclerotic rabbit iliac arteries for durations
up to 90 days. Arterial drug concentrations were measured with liquid chromatography-
mass spectrometry and compared between devices and models.
Results: A multivariant model is being assembled to determine the dependency on
model type, treatment type and duration. At all time points and for all types of DES,
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the mean tissue drug concentrations were lower in the atherosclerotic model compared
to the healthy. Tissue concentrations are plotted in the figure below.
Conclusion: For a given DES, the basic shape of the PK curves between healthy and
atherosclerotic models was similar. Tissue levels were lower in the atherosclerotic
model compared to healthy out to 90 days. Differences in tissue drug concentration in
atherosclerotic tissue may have implications for DES efficacy and delayed healing.
TCT-460
Anatomic Substrate for Renal Sympathetic Denervation: A Human Post-
Mortem Histological Study
Farrell O Mendelsohn1, Nicholas L Deep2, Daniel S Atherton3
1Princeton Baptist Medical Center, Birmingham, AL; 2University of Alabama School
of Medicine, Birmingham, AL; 3Baptist Health Systems, Birmingham, AL
Background: Hypertension remains an epidemic uncontrolled with pharmacologic
therapies. A novel catheter inserted into the renal artery has been shown to lower blood
pressure by ablating the renal sympathetic nerves with radiofrequency energy delivered
through the arterial wall (Ardian, Inc.). We report a histological study describing the
anatomic substrate for this technique, specifically the microanatomy of the renal
sympathetic nervous system.
Methods: Histological sections from proximal, middle, and distal renal artery segments
from 9 renal arteries (6 human autopsies) were analyzed. Nerves were manually
counted and their distance from the lumen-intima interface was measured using a
micrometer. The nerves were then categorized by location into 0.5mm-wide “rings”
that were arranged circumferentially around the renal artery lumen.
Results: The table shows the percent of nerves within each ring. 90.5% of all nerves
in this study existed within 2.0mm of the renal artery lumen. Additionally, the number
of nerves tended to increase along the length of the artery from proximal to distal
segments (proximal=216; middle=323; distal=417).
Conclusion: Our analysis indicates that a great proportion of renal sympathetic nerves
have close proximity to the lumen-intima interface and should thus be accessible via
renal artery interventional approaches such as catheter ablation. This data provides
important anatomic information for the development of ablation and other type devices
for renal sympathetic denervation.
TCT-461
Animal Studies on the Mechanisms and Radiofrequency Catheter Ablation of
the Syncope with Vasovaga1 Syncope —Radiofrequency Ablation of Cardiac
Nerve Attenuates Bezold-Jarisch Reflex in Canine
Chunshan Lu, Chengjun Guo, Dongping Fang, Li Guo, Dongfang He, Kejuan Ma,
Bing Liu, Jinghua Liu, Yingchuan Zhang
Cardiology, Beijing Anzhen Hospital, Beijing, China
Background: The Bezold—Jarisch reflex (BJR) is one of the main causes for
vasovaga1 syncope(VVS). Blocking the efferent pathways of the vagus ganglia in the
heart may attenuate the BJR.
Methods: Six mongrel dogs were anesthetized and their chest were opened through a
right thoracotomy to expose the Interventricular sulcus fat. Veratridine was injected
into the left ventricle at bolus doses of 15 ug/kg through a catheter to induce BJR. The
sinus cycle length (SCL), systolic arterial pressure (SAR), diastolic arterial pressure
(DAP), mean arterial pressure (MAP), left ventricle systolic pressure (LVSP), left
ventricle diastolic pressure (LVDP) and mean left ventricle pressure (MLVP) were
measured under the baseline and after ablation of fat pad; the changes of the above
parameters (SCL, SAP, DAP, MAP, LVSP, LVDP and MLVP) were
calculated. Then the same dose of veratridine was injected under mapping along the
mitral annulus, and potential nerve ablation and the changes of the above parameters
were observed.
Results: BJR was successfully induced in the 6 animals; the animals has prolonged
sinus cycle length (SCL) and decreased MAP and MLVP. After ablation, the
prolongation of SCL after injection of veratridine was markedly reduced [229.2 ± 92.3]
ms vs [39.3 ± 14.1] ms, p< 0.01. All the pressures were decreased after injection of
veratridine, with significant decrease found only for DAP and MAP both p< 0.05.
Conclusion: Ablation of the interventricular sulcus fat and endocardial nerve potential
fat can effectively attenuate the decrement of heart rate and the decrement of DAP and
MAP during the BJR induced by veratridine, which provides a basis for the treatment
of VVS.
TCT-462
Percutaneous Renal Sympathetic Denervation Exerts a Chronic Effect on Renal
Hemodynamics and Plasma Norepinephrine Levels Using a Novel Catheter for
Radiofrequency Ablation: Data from an Animal Study
Konstantinos Tsioufis1, Vasilios Papademetriou2, Kyriakos Dimitriadis1, Costas
Thomopoulos1, Dimitris Tsiachris1, Vivian Tran3, Cary Hata3, Euljoon Park3,
Apostolis Papalois1, Christodoulos Stefanadis1
1First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens,
Greece; 2Veterans Affairs Medical Center, George Washington University,
Washington, DC, WA; 3St. Jude Medical, 100 Technology Drive, Irvine, CA
Background: The effect of renal sympathetic denervation (RSD) on chronic
autoregulation of renal hemodynamics and plasma catecholamines has yet to be
adequately explored. We investigated the effect of RSD (1 month post ablation),
performed using a novel radiofrequency ablation catheter on renal hemodynamics
[average peak velocity (APV), renal flow reserve (RFR) and resistive index (RI)] and
on plasma norepinephrine levels.
Methods: In 9 anaesthetized female juvenile farm swines (mean weight 34.5 kg) a
0.014 inch Doppler flow wire was introduced in the renal artery for the measurement
of the APV under baseline and hyperemic condition that was induced by the bolus
intrarenal administration of dopamine (50μg/kg). RFR was calculated as the ratio of
hyperemic to basal peak velocity. RI was estimated as (peak systolic velocity – end-
diastolic velocity)/peak systolic velocity. APV, RFR and RI were measured before and
1 month after RSD. The RSD was achieved via the lumen of the main renal artery with
the novel catheter connected to a radiofrequency generator from St. Jude Medical
according to pre-specified algorithm. Plasma norepinephrine was estimated before and
1 month after ablation.
Results: In all animals, APV 1 month after RSD compared to APV before RSD was
significantly higher (30.21±13.14 vs 21.79±8.53cm/sec, p=0.035). Radiofrequency
RSD resulted in reduced RFR (1.36±0.25 vs 2.96±1.33, p<0.0001), RI (0.48±0.15 vs
0.74±0.07, p=0.003) and plasma norepinephrine levels (11.08±6.19 vs
17.76±11.9pg/ml, p=0.045), while no significant changes in the diameter of the renal
artery was observed after dopamine administration (p=NS).
Conclusion: Catheter-based RSD augmented APV and decreased RFR, RI and
norepinephrine levels persistently and significantly at 1 month post ablation in healthy
swines. These results support the chronic effect of RSD by the radiofrequency ablation
catheters on renal hemodynamic and catecholamines balance even in a healthy animal
setting.
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